Merck celebrates its 350th anniversary

MerckMerck, a leading science and technology company, will celebrate its 350th anniversary this year with customers, partners and employees under the motto "Past. Present. Future." In 1668, the pharmacist Friedrich Jacob Merck laid the cornerstone for what Merck is today - a vibrant, global science and technology company. "350 years, that's an incredible number, especially if you consider everything that has happened in the world of science between 1668 and today. We are proud of the many contributions Merck has made to research and development. And we will also continue to do exactly the same. In other words, we are infinitely curious about what is coming," said Stefan Oschmann, Executive Board Chairman and CEO of Merck.

A highlight of the anniversary year will be the "Curious2018 - Future Insight" conference in Darmstadt in mid-July 2018. This will be attended by more than 35 renowned international scientists - including five Nobel Prize laureates - who on three days will be presenting their work and discussing the future of science and technology. Merck is supporting this premiere event as the main sponsor. The speakers will present to an audience of around 1,000 guests from all over the world topics oriented to the main focal areas of the three Merck business sectors (Healthcare "Healthy Lives - new breakthrough therapies and diagnostics", Life Science "Life Reimagined - synthetic biology and beyond", and Performance Materials "Materials & Solutions - chemistry and beyond"). Other topics of the conference address questions regarding digitalization ("Vibrant Digital - the power of in silico") and new forms of collaboration ("Bright Future - new ways of working and collaborating").

"We are fighting cancer and other serious diseases. We are helping other companies to conduct research even more quickly and efficiently. And we are developing high-tech materials with which autonomous driving or foldable displays, for example, are becoming reality. We are doing all this in close partnership with top researchers around the globe. Therefore, we are very much looking forward to a huge celebration of research with the best of the best," said Stefan Oschmann.

Besides the five Nobel Prize-winning scientists - Joachim Frank (2017, Chemistry), Fraser Stoddart (2016, Chemistry), Bruce Beutler (2011, Medicine), Harald zur Hausen (2008, Medicine), Jean-Marie Lehn (1987, Chemistry) - further renowned representatives of the scientific and business communities, among others, will be present at "Curious2018 - Future Insight".

Another central event in Merck's anniversary year is the European ceremony on May 3, 2018 in a pavilion especially constructed for the celebrations. Around 900 guests from the worlds of politics and business are invited to this event in Darmstadt. Further regional ceremonies will take place in June in Shanghai, China and in October in Boston, USA.

In addition, as part of the European ceremony on May 3, the new Innovation Center will be officially opened. The newly designed and constructed building at the heart of Merck headquarters offers start-ups and company-internal innovation teams a five times larger area than was formerly available for working on innovation projects outside the existing business.

"It is a great joy to collaborate with young entrepreneurs. And who knows, one of the promoted business ideas might evolve some time into a company like Merck. After all, we also began as a start-up in 1668," said Stefan Oschmann.

Before Merck celebrates with external customers, partners and representatives of society, a celebration for employees will take place on April 18/19. This is planned for the around 50,000 people working at Merck worldwide and will extend over all continents for 24 hours.

"The celebration is a huge expression of our thanks to all our employees worldwide. With their work day by day, they ensure the success of our company. In Darmstadt we have many employees whose families have worked loyally for Merck over generations, which we highly esteem. Yet more and more talented people join Merck from all over the world, because they feel that Merck is a place where exciting things can be made to happen. In April, together with all of them, we will celebrate 350 years and the future," said Stefan Oschmann.

The other numerous events marking the 350th anniversary of Merck include the national "Jugend forscht" (Young Researchers) competition under the auspices of German Federal President Frank-Walter Steinmeier, which will take place in Darmstadt from May 24 to 27. The "Federal President's Award for Outstanding Work" is among the prestigious prizes awarded at the German national finals.

A highlight towards the end of the anniversary celebrations in autumn will be an Open Day on September 22, 2018 at global headquarters in Darmstadt. Interested visitors will then have the opportunity to take a look behind the scenes of the science and technology company Merck.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...